The biggest distribution channel to date of GLP-1 receptor agonists is the hospital pharmacies, which are estimated to be at 44.3% of the market share in 2025, being the major access to drug initiation, titration management, and distribution of specialty drugs
Slow dose escalation is critical because it allows the body to adapt to each receptor activation level before increasing it further
doi: 10.1016/S0021-9258(19)75835-9 40 KirkmanHNRolfoMFerrarisAMGaetaniGF
Rat model of 3-NP toxicity Male Lewis rats (weighing 260-300g) fed with either an unsupplemented control diet or a diet supplemented with 2% creatine or 1% CoQ 10 or a combination of the two for one week were implanted subcutaneously with osmotic minipumps (Model 2ML1, Alzet, Cupertino CA, filled with 3-NP 70mg/ml in PBS, pH 7.4) that delivered 3-NP 50mg per kg bodyweight daily for 7 days while remaining on the same diets (Ouary et al
Tin s Violi cho bit: khng c cch no sn phm ng th nghim c th gip ai gim cn v mc d cht bo qun m ng pht hin l an ton cho con ngi s dng, ng lo ngi rng n "c th cha bt c th g"